D18 Revumenib Monotherapy in Patients With Relapsed/Refractory KMT2Ar Acute Leukemia: Efficacy and Safety Results From the AUGMENT-101 Phase 1/2 Study

Abstract | Apr 15, 2024

Author

Aldoss I, et al.

Congress

Academy of Managed Care Pharmacy (AMCP)

Las Vegas, Nevada | Apr 15 – 18, 2024